Compare Hasbro, Inc. (HAS) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Medtronic PLC — how do they compare? Hasbro, Inc. trades at $92.69 (market cap $12.80B), while Medtronic PLC trades at $87.9 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 8.5× Hasbro, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Medtronic PLC for 63 Days on average.
| HAS | MDT | |
|---|---|---|
Market Cap | $12.80B | $109.38B |
Volume | 1,356,688 | 55,890,185 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $105.35 |
52-Week Low | $70.95 | $73.75 |
Typical Hold Time | 97 Days | 63 Days |
Enterprise Value | $14.99B | $128.71B |
Dividend Yield | 3.09% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $92.50, up 1.61% today, with a bullish technical outlook and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 20, 2026. Revenue is projected to grow to $5.0B in 2026, with net income rebounding to $794M. The company maintains a solid gross profit margin of 64.41% and positive operating cash flow, though it carries significant long-term debt of $3.38B.
The outlook is positive, driven by earnings momentum and cost-saving initiatives, but risks include high debt levels and competitive pressures. Analyst price targets suggest upside potential, with a consensus target of $107.60. Investors should monitor the upcoming earnings report for confirmation of growth trends and debt management progress.
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
